|
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer. |
|
|
Honoraria - AstraZeneca/MedImmune; Merck; Sanofi |
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Clovis oncology; Dendreon; Janssen Oncology; Seagen |
Speakers' Bureau - AstraZeneca; Merck Sharp & Dohme; Sanofi |
Research Funding - AstraZeneca/MedImmune (Inst) |
|
|
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme |
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst) |
|
|
Honoraria - Bayer; Janssen Oncology |
Consulting or Advisory Role - Merck Sharp & Dohme |
Research Funding - Amgen (Inst); Bayer (Inst); BioClin Therapeutics (Inst); Endocyte (Inst); Exelixis (Inst); Janssen Oncology (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst); Sarah Cannon Research Institute (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Janssen Oncology; Merck Sharp & Dohme |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Clovis Oncology; Eisai; Pfizer |
|
|
Employment - HealthONE; Sarah Cannon Research Institute |
Honoraria - Rocky Mountain Oncology Society |
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst) |
Speakers' Bureau - Total Health Conferencing |
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst) |
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute |
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
|
Stock and Other Ownership Interests - Regeneron |
|
|
|
Stock and Other Ownership Interests - Regeneron |
Patents, Royalties, Other Intellectual Property - Regeneron |
|
|
|
Stock and Other Ownership Interests - Agenus; Amicus Therapeutics; Bellicum Pharmaceuticals; Cel-Sci; Celldex; Gilead Sciences; Merck; Navidea; Newlink Genetics; Progenics; Sarepta Therapeutics; Soligenix; Sorrento Therapeutics; Veracyte |
Travel, Accommodations, Expenses - Regeneron |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Regeneron |